Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs

Core Insights - The FDA has granted conditional approval for Credelio Quattro-CA1, expanding treatment options for New World screwworm infestations in dogs and cats, alongside existing products Credelio and Credelio CAT [1][2][14] - The approval is based on a study showing 100% efficacy of lotilaner against New World screwworm larvae within 24 hours of treatment in naturally infested dogs [2][11] - Elanco aims to provide comprehensive parasite protection with Credelio Quattro, which now offers coverage for seven types of parasites, including the newly added New World screwworm [4][8] Product Details - Credelio Quattro provides protection against six types of parasites, including ticks, fleas, and heartworm disease, as well as three types of intestinal parasites [4][10] - The product is indicated for dogs and puppies aged 8 weeks and older, weighing 3.3 pounds or greater [10][11] - New product labeling reflecting the conditions of use for both Credelio Quattro and Credelio Quattro-CA1 will be available in 2026 [3] Market Context - There have been 14 reported cases of New World screwworm within 400 miles of the U.S.-Mexico border, highlighting the urgency for effective treatment options [1] - The New World screwworm can infest all warm-blooded animals, including pets and livestock, emphasizing the need for proactive measures in animal health [5][6] - Elanco's commitment to life cycle management of the Credelio Quattro brand has resulted in three positive label advancements in under 11 months since its launch [4]